From Zacks Tilray, Inc. TLRY will release financial results for the fourth quarter and fiscal 2021 ended May 31, 2021, before market open on Jul 28.
Why a Likely Positive Surprise Our proven model predicts an earnings beat for Tilray this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Earnings ESP for Tilray is +14.47%.
Factors at Play Tilray is a leading global cannabis-lifestyle and consumer packaged goods company.
In May 2021, the company completed its previously announced business combination with Aphria. Each Aphria shareholder received 0.8381 of a Tilray share for each Aphria common share held on Apr 30, 2021. The combined company is now one of the leading cannabis-focused consumer packaged goods companies, with the largest global geographic footprint in the industry.
This will be the first quarter of reporting post the merger. Tilray has a strong consumer packaged goods presence in the United States. The combination with Aphria has strengthened its infrastructure with the addition of SweetWater, a leading cannabis lifestyle branded craft brewer. Performance in the quarter under review has likely got a boost with the incremental contribution.
In June 2021, Tilray announced the launch of a new medical cannabis brand, Symbios. Tilray also announced new high-potency, medical cannabis topicals under the Aphria brand designed to target inflammatory joint disease by regulating tissue inflammation when applied topically to the skin.
Revenues have likely shown a recovery as COVID-related lockdowns eased in Canada and Germany.
The new company expects to generate approximately $81 million of annual pre-tax cost synergies within eighteen months and plans to achieve cost synergies in the key areas of cultivation and production, cannabis and product purchasing, sales and marketing, and corporate expenses. Further updates on the same are awaited with the results.
J
Delly, it doesn’t matter how great the earnings are for MSOs. Profits aren’t good for MSOs cuz tax laws more importantly, MSOs trading volume is anemic cuz the banks and investment firms can’t buy stocks on pink sheets. Until MSOs are allowed to uplist, Certain LPs will rip higher and lower on news compared to MSOs…fact. Tilray 3 month average is 25 million shares a day and Curaleaf is 560 million shares. Those are the facts, Delly
E
On July 28th, The world will know who will be King of MJ industry with the highest market share in EU &CAN and the lowest cost of products, Shorts can manipulate SP for moment but are not able to change this basic facts!!
J
The nice thing about Tilray is there are a couple possible upcoming Catalyst that can propel the share price higher cuz we are a global company. #1 U.S. news of new bill moving forward #2 Germany Rec news 3. Portugal and Israel.
H
Canadian Cannabis Sales Increased 68% in May to $313 Million
D
Wake up America! TLRY is upgraded Strong Buy at these low prices. Financial Institutions again have quietly accumulated lots of TLRY shares, increase to 310 institutions (increased from 302 few days ago) holding 17.72% of TLRY shares (increased from 16.41%). TLRY will appreciate quickly on good news SOON.
E
Whatever Pablo Zuanic and John Zamparo say, do the opposite. Works every time. I would have to concur with other posts. The ER is going to be a nice surprise. Irwin wants a Yes vote. No way he's going to get it with a plunging stock the day previous. Tilray was already hovering close to profitable. With lowest cost of production, EU opened up, Canada starting to awaken and majority market share it's going to 🚀.
D
Alcohol and Tobacco companies may buy TLRY company at premium price in the near future. Thus, don't sell. Buy more TLRY shares, Be patient for LONG TERM appreciation significantly.
S
I voted FOR all of this year's proposals, in line with the board's recommendations. I will not change my vote if the earnings report is disappointing. These changes are needed to move the company forward and continue its growth and dominance.
P
Market growth As it is the case with any product, we can always foretell its chances of success by monitoring the stocks and shares on the market. With that in mind, saying that cannabis has a strong position in the market would be an understatement. Basically, the figures speak for themselves.
The global legal marijuana market should be worth almost $150 billion by 2025. It is hard to state which other agricultural product could come near that figure. The forecast is very optimistic, predicting a continuous growth, and market analysts do not seem to worry about the market eventually becoming saturated, which is quite unusual.
Therefore, if you’re thinking about investing in legal marijuana stocks, now would be the time to purchase some since the prices are only going to increase. $CGC
R
In my opinion at this price Tilray is a steal its close to 52 week low. anyone have any suggestions of where this stock is headed please share. What is this Dilution of shares everyone is talking about please explain is this good or bad for the stock
J
The danger of this message board and the entire internet is that you do not know who is telling the truth and who is spreading misleading information for personal gain. I was am Alphria stock holder and now own the merged Tilray company. I will keep it long term, knowing very well it is a speculative stock which could make me a lot of money over time or could go banckrupt and lose all my money. This company has potential but, it is not a sure thing. Legalizing cannabis in the U.S. could be good or bad for Tilray. The bad is major U.S.Companies with 10 times the cash of Tilray could get in the business make it very difficult for Tilray to penetrate the market successfully. Tliray also has to prove it can generate positive cash flow and make a profit. This is a major reason the stock is stuck in a rut right now. Many of you believe the voting for additional stock ahead of earnings was a sign that the quater results next week will be a good , but understand, it may be a bad one. It's possible they know they are reporting a bad quater and would have no chance for a yes vote if they tried after they report. I'm not saying the quarter will be bad or good, but that this is a speculative stock and that currently you should only be investing money that you can afford to lose
s
Tilly will skyrocket after earnings that’s why they want you to approve more shares.
H
everyone go enjoy the summer don't even think about stock or Tilray come back here in September trust me we'll be back in the 25-30$ range and November 45$ just go out and relax for now, peace.
E
It Will Finally Be Acknowledged That Tilray Is Number One after next week’s earnings report. That’s when Longs will be partying 🥳🥳🥳 Catch The Tilray Train Before It’s Too Late
E
When Aphria took control of Tilray, they immediately closed two of Tilray's largest production facilities in Ontario. MJ now comes from one of Aphria's two state of the art facilities in Leamington. Not only will they realize huge cost savings from the closures, but Tilray's cost per gram just fell to the lowest in the world. Aphria invested heavily in robotics in the early days. It's built in efficiencies and the fact it owns a major pharmaceutical company in Europe translates to profits! When you look at the synergies and how Tilray will benefit from Aphria's costs per gram, we could be pleasantly surprised next week.
J
Rough time for our long term Tilray investors! Losses just started mounting! Added another 5000 shares at 13.54 today. Going to hold for 3 -5 years Wish you all the best fellow Tilray long investors!
J
I was just looking at Canopy’s share price over the last year 52 week high $71.60 and today $24.68. Just saying it is not just a Tilray thing as the bashers would like you to believe.
J
If Tilray has a positive surprise earnings report, to the moon we go
B
In the past month this stock has lost over 22%. It's time to start heading back the other way now. It's oversold!
Tilray, Inc. TLRY will release financial results for the fourth quarter and fiscal 2021 ended May 31, 2021, before market open on Jul 28.
Why a Likely Positive Surprise
Our proven model predicts an earnings beat for Tilray this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Earnings ESP for Tilray is +14.47%.
Factors at Play
Tilray is a leading global cannabis-lifestyle and consumer packaged goods company.
In May 2021, the company completed its previously announced business combination with Aphria. Each Aphria shareholder received 0.8381 of a Tilray share for each Aphria common share held on Apr 30, 2021. The combined company is now one of the leading cannabis-focused consumer packaged goods companies, with the largest global geographic footprint in the industry.
This will be the first quarter of reporting post the merger. Tilray has a strong consumer packaged goods presence in the United States. The combination with Aphria has strengthened its infrastructure with the addition of SweetWater, a leading cannabis lifestyle branded craft brewer. Performance in the quarter under review has likely got a boost with the incremental contribution.
In June 2021, Tilray announced the launch of a new medical cannabis brand, Symbios. Tilray also announced new high-potency, medical cannabis topicals under the Aphria brand designed to target inflammatory joint disease by regulating tissue inflammation when applied topically to the skin.
Revenues have likely shown a recovery as COVID-related lockdowns eased in Canada and Germany.
The new company expects to generate approximately $81 million of annual pre-tax cost synergies within eighteen months and plans to achieve cost synergies in the key areas of cultivation and production, cannabis and product purchasing, sales and marketing, and corporate expenses. Further updates on the same are awaited with the results.
As it is the case with any product, we can always foretell its chances of success by monitoring the stocks and shares on the market. With that in mind, saying that cannabis has a strong position in the market would be an understatement. Basically, the figures speak for themselves.
The global legal marijuana market should be worth almost $150 billion by 2025. It is hard to state which other agricultural product could come near that figure. The forecast is very optimistic, predicting a continuous growth, and market analysts do not seem to worry about the market eventually becoming saturated, which is quite unusual.
Therefore, if you’re thinking about investing in legal marijuana stocks, now would be the time to purchase some since the prices are only going to increase. $CGC
Added another 5000 shares at 13.54 today.
Going to hold for 3 -5 years
Wish you all the best fellow Tilray long investors!